A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess
the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous
Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or
uncontrolled hypertension